Navigation Links
New Research Study Seeks Improved Quality of Life for People in the Future with Schizophrenia

Miranda Chakos, MD of SUNY Downstate Medical Center leads research for local patients

Brooklyn, NY (PRWEB) August 26, 2008 -- Imagine going through the day without the ability to concentrate and focus on the things you enjoy and important tasks that you need to complete. Think what it would be like, struggling to remember what you just talked about or learned a short time ago. Consider how you would feel if you couldn't even accomplish simple tasks, such as making a phone call, grocery shopping or scheduling an appointment.

We all have challenging moments . . . but for people suffering from schizophrenia, these frustrations are a way of life, virtually every day. People with schizophrenia struggle to concentrate, remember and learn. These deficits associated with the thinking process are called cognitive impairments, making it difficult to accomplish the demands of everyday life, both big and small.

Managing the demands of daily life is made easier when individuals with schizophrenia maintain a stable regimen of medication -- even more so for those with trusted family members or caregivers to help oversee the individual's personal affairs and coordinate care. Despite the challenges, most people with schizophrenia and their caregivers are searching for a better quality of life.

Fortunately, there is hope, thanks to a new [investigational drug research study] now underway in the Brooklyn, NY area. The primary goal of this study is to evaluate the safety and effectiveness of an investigational drug in improving cognitive functioning for people with schizophrenia, using a new evaluation tool called [MATRICS] (Measurement and Treatment Research to Improve Cognition in Schizophrenia). This study is unique because participants are not required to change their already-stable medication regimen. Rather, the new investigational medication is added to their currently established treatment.

Candidates for this study must be 18 to 65 years old, diagnosed with schizophrenia at or before age 35 and currently taking one of five medications for schizophrenia which include olanzapine, risperidone/paliperidone, quetiapine or aripiprazole. Participants must also be considered outpatient (living in the community). [Qualified study participants] will receive all investigational medication and study-related care at no cost, and may also receive compensation for travel.

Miranda Chakos, MD of SUNY Downstate Medical Center seeks participants for this new study. If you or someone you know suffers from schizophrenia, please contact us for additional information at 888.988.6736. Further details about the study are also available at

Hal Coxon
Axiom Accelerated Clinical Patient Recruitment
(847) 919-1005

# # #

Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Research finds Americas elderly suffering abuse
2. Operations research promises continued gains for HIV treatment in resource-limited countries
3. SNM and ASTRO team up to advance molecular imaging and cancer research
4. CytoViva(R) Introduces Breakthrough Nano-Technology Research Tool
5. The Brain Aneurysm Foundation Announces 2008 Research Grant Recipients
6. Reeve Foundation Recruits Distinguished Stem-Cell Neurobiologist - The Salk Institutes Samuel L. Pfaff, Ph.D. - to its International Research Consortium
7. UTMB researchers test new vaccine to fight multiple influenza strains
8. AIAM Sponsors Leading Child Safety Research Initiative
9. UNC researcher aims to unmask cancer cells to trigger bodys immune system
10. STEMCELL Technologies Introduces AggreWell™400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research
11. UCSF faculty receive $13.7M from CIRM for stem cell research
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: